OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

OnKure Therapeutics announced a virtual key opinion leader event for July 15, 2026, featuring Dr. Benjamin Cravatt and Dr. Robert Abraham to discuss its PI3Kα inhibitor portfolio. The session will focus on the company's next-generation programs OKI-345 for breast cancer and OKI-355 for vascular anomalies, designed to selectively target mutant PI3Kα.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.